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Introduction
It has been known for many decades that ischemic preconditioning (IPC) of the brain is an effective approach to elicit ischemic tolerance against subsequent lethal stroke 1-3 . However, whether IPC provides short-lasting or long-lasting neuroprotection is still debated. Two timeframes of IPC-mediated ischemic tolerance have been reported in the literature 3 : 1) a rapid timeframe that emerges within minutes and provides transient protection with a duration of several hours, and 2) a delayed timeframe that emerges within hours to days and confers a relatively longer protection period (> 7 days). Rapid preconditioning only provides short-lasting protection that wanes within 1-3 days 4, 5 . Although several studies have reported that delayed non-ischemic preconditioning offers long-lasting protection against ischemic injuries [6] [7] [8] [9] , it remains unclear if delayed ischemic preconditioning offers similarly long-lasting neuroprotection.
As long-lasting protection would be more clinically meaningful, there is an urgent need to determine if IPC simply delays ischemic brain injury or reduces the magnitude of the injury in a persistent fashion.
Post-stroke cognitive impairments affect up to one-third of stroke survivors 10 and are becoming increasingly prevalent in the elderly population 11 . However, whether IPC can reduce post-stroke cognitive impairments is not known. As there is no treatment available against poststroke cognitive impairment and dementia, it is important to investigate if IPC can offer some degree of protection against post-stroke cognitive impairment.
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a master transcription factor regulating cellular redox equilibrium by inducing the expression of myriad antioxidant genes 2, [12] [13] [14] [15] [16] . In our previous study 17 , we discovered that delayed IPC in mice activates the Nrf2 pathway, as indicated by the upregulation of heme oxygenase 1 (HO-1) in neurons, astrocytes, and endothelial cells. Among the ten categories of Nrf2 activators 18 , the Michael reaction acceptors are the only endogenous activators of this transcription factor. Michael reaction acceptors are electrophiles, and the majority are end products of lipid peroxidation, including 4-hydroxynonenal (4-HNE) from omega-6 fatty acids and 4-hydroxy-hexenal (4-HHE) from omega-3 fatty acids [19] [20] [21] [22] .
Previous in vitro studies have demonstrated that preconditioning (PC) of astrocytes activated astrocytic Nrf2, which protected neurons against ischemic injury in astrocyte-neuron J o u r n a l P r e -p r o o f Journal Pre-proof co-cultures 23, 24 ; however, it is unknown if direct PC of neurons can also prevent ischemic injury.
It is well known that neurons are highly sensitive to oxidative stress and that PC is associated with sublethal oxidative stress 23, [25] [26] [27] . On this backdrop, we hypothesize that PC may lead to mild oxidative stress in neurons via the generation of lipid electrophiles, followed by induction of self-defense mechanisms through electrophile-mediated Nrf2 activation and Nrf2-mediated transcription of Phase 2 antioxidant genes.
To address the abovementioned gaps and explore the potential mechanisms behind IPC, we choose delayed IPC in the present study, as it confers more robust neuroprotection than rapid IPC 28 and is dependent upon genetic reprogramming and de novo protein synthesis 2, 25, 29 . We report that IPC can protect the brain against long-term sensorimotor and cognitive dysfunction and tissue loss after experimental ischemic stroke through the activation of Nrf2. Finally, to emphasize the importance of Nrf2 activation in long-lasting neuroprotection, we also performed a translational study with a potent and blood-brain barrier-permeable Nrf2 activator 2-cyano-3,12-dioxo-oleana-1,9(11)-dien-28-trifluoethyl amide (CDDO-TFEA), which exerted similar robust and enduring neuroprotective effects.
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Methods

Animals and blinding
This study was designed in accordance with ARRIVE guidelines. All animal experiments were approved by the University of Pittsburgh Institutional Animal Care and Use Committee (IACUC) and carried out in accordance with the Stroke Treatment and Academic Roundtable (STAIR) guidelines and the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Adult male C57BL/6 mice and Nrf2 knockout (KO) mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and housed with a 12:12 hr light-dark cycle at 22-24°C. The mice were randomly assigned to sham surgery (Sham), Stroke, and IPC+Stroke using a lottery-drawing box. All the outcome assessments were performed by investigators blinded to the group assignments.
Middle cerebral artery occlusion (MCAO)
Male wild-type (WT) and Nrf2 KO mice underwent MCAO on the left side for 12 min to induce IPC 3, 30 , and 60 min to induce preclinical stroke 20, 31 . These procedures were followed by reperfusion for the indicated durations. The interval between IPC and stroke was three days. The effects of IPC on ischemic outcomes in female mice have been reported in our previous study 17 .
MCAO was performed with standard, previously published procedures 17, 20, 31 . In brief, mice were anesthetized with 1.5% isoflurane in a 30% O 2 /70% N 2 O mixture under spontaneous breathing, and rectal temperature was maintained at 37.0 ± 0.5°C with a temperature-regulated heating pad. Mean arterial blood pressure was monitored with a tail-cuff. Under a surgical microscope, the left external, internal, and common carotid arteries were exposed through a midline neck incision. After coagulating and cutting the branches of the external carotid arteries, a 7-0 monofilament nylon suture with a silicone coat was inserted in the lumen of the external carotid artery and advanced to the origin of the middle cerebral artery via the internal carotid artery. The success of ischemia was confirmed by the measurement of regional cortical cerebral blood flow (rCBF) and the examination of neurological deficits 17 .
Drug preparation and administration
2-cyano-3,12-dioxo-oleana-1,9(11)-dien-28-trifluoethyl amide (CDDO-TFEA) was purchased from Cayman Chemical (Ann Arbor, MI) and prepared according to previous reports 32 . The mice received CDDO-TFEA (25 μmol/kg) or vehicle by gastric gavage in 200-μL volumes for three consecutive days before MCAO.
Behavioral tests
Sensorimotor functions were assessed with the Rotarod and adhesive removal tests beginning in the first week after stroke, and long-term cognitive function was assessed using the Morris water maze test for five weeks after stroke.
Rotarod test
Mice were trained for three consecutive days before surgery and were examined up to 35 days after stroke. After the mice were placed on the rods (IITC Life Science Inc., Woodland Hills, CA), the rods began to rotate and accelerate to 40 rpm within 300 s. The maximal length of each trial was 300 s. Results are presented as the duration that the mice were able to remain upright on the rods 17, 33, 34 .
Adhesive removal test
Mice were trained for five consecutive days before surgery and were tested up to 7 days after stroke. An adhesive paper patch (3 × 3 mm) was attached to the distal radial region of the right forelimb. The time to remove the patch from the forelimb was recorded 17, 20, 35 .
Morris water maze test
Mice were first trained in the Morris water maze for three days before surgery, and the tests were initiated 31 days after stroke when motor deficits have largely recovered in this model. The 
Primary neuronal cultures and oxygen-glucose deprivation (OGD)
Primary cultures of the rodent cortical neurons were dissected from E16-18 fetuses and maintained in Neurobasal media supplemented with B27 (Gibco, ThermoFisher Scientific, Pittsburgh, PA), as previously described 20, 31, 37 . The experiments were performed 10-14 days after seeding cells in culture plates.
OGD was used to mimic in vitro ischemia with standard, previously published procedures 31 .
A brief duration of OGD (12 minutes) was used as a PC stimulus, prior to 1-h lethal OGD. The interval between PC and OGD was 16 h, and cells were returned to normal culture media and normal oxygenation for 24 h after OGD before harvest.
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Western blots and Western slot blots
Total cell lysates from primary rat neurons were subjected to standard Western blot assays, as previously described 20, 31 17, 38 . The remaining procedures were the same as described above for the Western blots.
Cell death and viability
Cell death and viability were measured by the Live/Dead cell viability assay (Molecular Probes, ThermoFisher Scientific, Pittsburgh, PA), the lactate dehydrogenase (LDH) release assay (Pointe Scientific Inc., Canton, MI), and the methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay (Sigma-Aldrich, St. Louis, MO). These assays were performed in triplicate, on at least three independent occasions.
The Live/Dead cell viability assay was performed according to the manufacturer's instructions (Molecular Probes, Eugene, OR), as previously described 17, 20 . In this assay, red dots 
Statistical analyses
The results are presented as the mean ± SD for the in vivo studies and mean ± SEM for in vitro studies. The difference between means was assessed by Student's t-test (single comparisons) or by the appropriate analysis of variance (ANOVA, for multiple comparisons). GraphPad Prism software (version 7.0, La Jolla, CA, USA) was used for statistical analyses. A p value  0.05 was deemed statistically significant.
Results
IPC protects against long-term cognitive defects and brain tissue loss
To determine if IPC offers long-term neuroprotection in mice, we performed the Rotarod test up to 5 weeks after stroke. As shown in Fig. 1A , IPC significantly improved sensorimotor function in this assay, for at least five weeks post-injury. To assess post-stroke cognitive function, we performed the Morris water maze tests in the fifth week after stroke. As shown in Fig. 1B -D, IPC significantly improved learning and memory capacities after stroke. Notably, swim speeds did not differ across groups, suggesting that the water maze results could not be attributed to differences in gross motor skills ( Supplementary Fig. 1A ). Immediately following the memory test at 35 d post-stroke, the mice were sacrificed, and the brains were harvested for J o u r n a l P r e -p r o o f immunostaining with the neuronal marker MAP2 to assess brain tissue loss. As shown in Fig. 1E , IPC significantly reduced tissue loss compared to the stroke group, indicating a long-term neuroprotective effect of IPC. Hippocampal neurons play an important role in learning and memory, particularly those in the CA1 fields. To investigate whether stroke and IPC affect CA1 neuron viability, we counted neurons immunostained for the specific neuronal marker NeuN. As shown in Supplementary Fig. 2 , there were no significant differences between control and preconditioned groups in NeuN+ cell counts after MCAO. We also performed TUNEL staining to detect dead cells. While TUNEL-positive signals were visible at the rim of the infarction in the cortex, little signals could be detected in the hippocampi of both groups (Data not shown).
Nrf2 plays a key role in IPC-mediated long-term neuroprotection in vivo
Next, we tested the hypothesis that Nrf2 is essential for IPC-mediated neuroprotection. For these mechanistic experiments, we preconditioned Nrf2 knockout (KO) mice and induced stroke three days later. As expected, neither sensorimotor function ( Fig. 2A ) nor cognitive function (Fig. 2B-D and Supplementary Fig. 1B ) was preserved by IPC in Nrf2 KO mice. The measurements of brain tissue loss at 35 d post-stroke ( Fig. 2E ) further confirmed the reduction of IPC-mediated protection in Nrf2 KO mice. Collectively, these findings indicate that Nrf2 plays an important role in IPC-mediated long-term ischemic tolerance in vivo.
In vitro PC neuroprotection against OGD is associated with mild oxidative stress
As mentioned in the Introduction, among the ten categories of Nrf2 activators 18 , the only endogenous activators are lipid electrophiles, the end products of natural lipid peroxidation. Our previous work confirmed that IPC leads to the generation of sublethal amounts of 4-HNE, which then activates Nrf2 in mouse brains 17 . In the present study, we examined whether this outcome also mediates PC-afforded neuronal protection in vitro.
Consistent with previous reports, PC protected primary neuronal cultures from lethal OGD, as indicated by live/dead staining and cell counting ( Fig. 3A-B) , as well as the MTT and LDH release assays ( Fig. 3C-D) 39 . In addition, PC also increased the levels of 4-HNE modified proteins ( Fig. 3E ) and HO-1, a reliable marker of Nrf2 activation 20, 31 (Fig. 3F) . Notably, the J o u r n a l P r e -p r o o f increase in 4-HNE and HO-1 by PC was lower than with lethal OGD (Fig. 3E-F ), suggesting that PC only elicits mild or sublethal oxidative stress, consistent with our in vivo findings 17 . These data support the hypothesis that PC elicits a sublethal degree of oxidative stress and protects against OGD-induced neuron death.
Nrf2 plays a key role in PC-mediated neuroprotection in vitro
Next, we determined whether Nrf2 was critical in PC-afforded neuroprotection using neurons derived from Nrf2 KO fetal mice. As expected, PC-mediated protection was abolished in Nrf2 KO neurons, as evidenced by Live/Dead staining and cell counting ( Fig. 4A-B ), as well as MTT ( Fig. 4C ) and LDH assays ( Fig. 4D ), indicating an indispensable role for Nrf2 in PC.
Pharmacological activation of Nrf2 robustly preconditions the brain in vivo
A major goal in researching the mechanisms behind IPC is to translate the corresponding mechanism through pharmaceutical approaches 40, 41 . To determine if the Nrf2-mediated protective mechanism is clinically translatable, we activated Nrf2 using the compound CDDO-TFEA, a potent triterpenoid with high blood-brain barrier permeability 42 . As shown in Fig. 5 , CDDO-TFEA pretreatment improved sensorimotor function ( Fig. 5A-B ) and learning and memory up to 35 days post-injury ( Fig. 5C-D) , without affecting gross motor functions ( Supplementary Fig 1C) . As expected, these neurological improvements were associated with reduced brain tissue loss (Fig. 5E ). These results suggest that Nrf2 is an attractive target for pharmacological preconditioning against stroke in vivo.
Discussion
The present study is the first to demonstrate that IPC provides long-lasting neuroprotection up to 35 days after stroke. IPC preserves both the functional and structural integrity of the brain in an Nrf2-dependent manner. At the cellular level, PC confers neuronal ischemic tolerance by lipid electrophile generation and Nrf2 activation. Finally, the use of CDDO-TFEA revealed that the Nrf2-mediated protective mechanism might be clinically translatable.
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Previous studies have reported that both rapid and delayed IPC only elicit short-term protection against global ischemia 4, 43 . In focal cerebral ischemia models of embolic or thrombotic stroke, long-lasting protection has only been reported following non-ischemic preconditioning, such as lipopolysaccharide 7 , spreading depression 8 , and asphyxia 6, 9 ; thus, whether long-lasting protection can be elicited by delayed ischemic PC was not known. Here, we
show that delayed IPC confers long-term protection against stroke at both the structural and functional levels, as indicated by cognitive tests and infarct volume measurements up to 35 days after stroke.
Our findings of spatial memory tests are particularly important because post-stroke cognitive impairment and dementia are increasingly prevalent in the elderly population and pose a heavy socioeconomic burden 11, 44 . The mechanisms of cognitive protection are unclear. Our results show that there no obvious CA1 neuronal loss, consistent with reports that the hippocampus is supplied by the posterior cerebral artery but not by the middle cerebral artery (MCA), and that MCAO does not cause frank hippocampal damage. However, MCAO causes white matter damage [45] [46] [47] , and IPC reduces white matter injury, including the fibers that connect the hippocampus and thalamus 48, 49 . Aside from the hippocampus, other brain regions are also critical for learning and memory, such as the frontal, parietal, and temporal lobes 50 , and the MCA supplies the blood to these regions. As IPC significantly reduces infarct volumes after MCAO, the preserved brain regions likely contribute to the improvement of cognitive function.
However, further experiments are needed to elucidate the exact mechanisms underlying cognitive protection in IPC.
Upon exploration of the mechanism underlying IPC-afforded neuroprotection, we focused on oxidative signaling and de novo protein synthesis. We observed that several Nrf2-controlled proteins are upregulated after IPC, including HO-1, glutamate-cysteine ligase, and the thioredoxins. When Nrf2 gene expression was ablated, ischemic tolerance was lost in the present study, consistent with previous studies revealing an indispensable role for Nrf2 23 . Nrf2 has also been reported to mediate preconditioning with hyperbaric oxygen 51 , limb ischemia 52 , and inhaled anesthetic gas 53 . Thus, the engagement of the Nrf2 pathway serves as a generalizable mechanism underlying ischemic tolerance against stroke.
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We previously found that IPC leads to a mild increase in 4-HNE and widespread Nrf2 activation in the brain. Cortical neurons displayed a diffuse, albeit mild increase in HO-1 expression after IPC in mice 17 . In the present study, we further reported that PC protected neurons via Nrf2 activation and that this may be mediated by the generation of lipid electrophiles.
To our knowledge, we are the first to report the involvement of low levels of electrophiles in PCmediated neuronal Nrf2 activation and self-protection against ischemic injury.
It is not fully understood how Nrf2 activation after IPC offers long-lasting protection against ischemic brain injury. De novo protein synthesis, controlled by transcription factors, is essential for the emergence of ischemic tolerance 2, 54 . A key component of IPC is the interval between IPC and lethal stroke, which is necessary for subsiding the sublethal injury of IPC and the synthesis of new proteins. Nrf2 is a transcription factor that upregulates anti-oxidative enzymes 13, 55 . Unlike small molecular antioxidants (glutathione, vitamin C, vitamin E) that are consumed during their anti-oxidative actions, anti-oxidative enzymes are not consumed during antioxidative reactions, as they operate catalytically; therefore, they exert long-term anti-oxidative effects 56 . In addition to these enzymes, Nrf2 also upregulates anti-apoptotic proteins and several cell-type-specific proteins, which may also contribute to the long-lasting protection of IPC.
These pre-existing cytoprotective proteins may reduce ischemic brain injury after lethal MCAO, especially in the penumbra regions. However, it is important to note that Nrf2 may not be the only transcription factor that contributes to IPC-mediated protection. Peroxisome proliferatoractivated receptor-gamma (PPARγ) 57 , heat shock factor-1 58 , and hypoxia-inducible factor-1 also serve to reestablish redox and proteostatic equilibrium 59 . Other transcriptions factors, such
as PPARγ, can also be activated by lipid electrophiles 60, 61 .
There are two major goals of IPC studies. First, a superior understanding of the biological mechanisms underlying preconditioning is expected to accelerate the development of new neuroprotective strategies. To this end, pharmacological activation of Nrf2 with CDDO-TFEA for three days significantly reduced neurobehavioral dysfunction and infarct volume induced by focal ischemic stroke. These findings support our previous report that pretreatment with CDDO -Im protects hippocampal CA1 neurons after global ischemia in rats 31 . Pharmaceutical preconditioning with alternative Nrf2 activators such as sulforaphane, triterpenoid derivatives, or fish oil 31, 62 also holds translational promise. Triterpenoid derivatives or fish oil might be especially useful in patients with a history of transient ischemic attacks or at high risk for stroke.
Post-ischemic treatment with potent electrophiles to expedite and enhance Nrf2 activation has translational potential and may be more effective in combination with reperfusion therapy 31 .
The second goal of IPC studies is to guide its application in the clinic. Clinical investigations have shown that IPC can induce ischemic tolerance in humans [63] [64] [65] . Based on current diagnostic approaches and techniques of ischemic stroke, however, it is difficult to predict when a stroke will occur, even in persons with obvious risk factors. Although this limits the use of IPC before the stroke onset to attenuate ischemic brain injury, t here are also several scenarios in which IPC can be purposefully induced in the clinic. For example, IPC can be induced in patients with anticipated ischemic events, such as vascular neurosurgery 3, 66 . Another tool to reduce stroke morbidity and infarct size in the clinic is remote preconditioning, which can be administered non-invasively and inexpensively with a blood pressure cuff 67 . Finally, pharmaceutical preconditioning and alternative electrophiles may also offer promise in the clinic, especially those with strong potency, such as triterpenoid derivatives, sulforaphane, resveratrol, or fish oil 20, 31, [68] [69] [70] . The latter method can be especially useful in patients with a history of transient ischemic attacks or at high risk for stroke. Future studies to determine Nrf2 activation in fibroblasts or plasma cells harvested from remotely preconditioned patients might also shed light on the underlying mechanisms.
Summary
In conclusion, we report here that IPC-mediated ischemic tolerance provides long-lasting protection against ischemic brain injury. Based on this study and our previous work, it seems likely that IPC elicits the generation of lipid electrophiles that activate the Nrf2 pathway and induce long-lasting protection. These mechanisms are applicable to the clinic, as oral administration of CDDO-TFEA provided a similar degree of long-term protection. Therefore, targeting Nrf2 is a promising strategy to protect the mammalian brain against stroke. 
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Figure legends
Visible abstract (A) Ischemic stroke is associated with severe oxidative stress, which induces the generation of large amounts of lipid electrophiles and produces long-term cognitive deficits and brain tissue loss. (B) We discovered that ischemic preconditioning (IPC) provides enduring protection against long-term stroke-induced sensorimotor deficits, cognitive deficits, and brain tissue loss.
In comparison with stroke, IPC only creates mild oxidative stress, which leads to the generation of subtoxic levels of lipid electrophiles followed by Nrf2 activation. This mechanism has translational potential, as the Nrf2 inducer CDDO elicits comparable protection in vivo. were not due to alterations in gross motor function. 
